What is the problem with Bayer Trasylol (Bayer aprotinin)?
Bayer Trasylol was approved by the FDA and sold worldwide for the last 13 years and
has been administered to an estimated one million patients. Bayer Trasylol now proves
to double a patient's risk of kidney failure, and increase the risk of Trasylol
heart attack, heart failure, stroke, and encephalopathy brain disease during coronary artery bypass surgery. Thus there are now efforts to move forward with a Trasylol class action lawsuit and invididual claims.
The problem with Bayer Trasylol is that the lack of drug
safety is not only too common but perhaps misrepresented by multi-billion dollar
pharmaceutical companies who may be more concerned about investor relations than
patients' health. (Read More)
